首页> 外文学位 >Comparative in virto diffusion study for Lovastatin transdermal delivery system.
【24h】

Comparative in virto diffusion study for Lovastatin transdermal delivery system.

机译:洛伐他汀透皮给药系统的体外扩散比较研究。

获取原文
获取原文并翻译 | 示例

摘要

The major risk factor for the development of coronary heart disease is a high concentration of plasma cholesterol, especially low density lipoprotein (LDL) cholesterol. The single biggest cause of heart and blood vessels disease is atherosclerosis, on the hardening of arteries. Atherosclerosis is silent and fatty infiltration of coronary arteries ultimately leading to coronary heart disease (CHD). Lovastatin is one of the ideal medications which is used in the therapeutic treatment of this diseases.;The present study determines the transdermal delivery of Lovastatin through cellulose membranes and human cadaver skin, and to evaluate the effect of enhancers.;In vitro release studies were carried out by Franz diffusion cells at 37°C. Different concentrations of the Lovastatin solution (0.025%, 0.05%, and 0.1%) were formulated with Methocel gel at four different concentrations (0.125%, 0.25%, 0.5%, and 0.75%). Four different enhancers were used (Caprylic acid, Capric acid, Lauric acid, Sodium Lauryl Sulfate) at 0.1% concentration. The donor compartments contain either the Lovastatin solution or gel. Receiver compartment contain a 1:1 ratio of ethanol and water. The cellulose membrane and human cadaver skin were used to study diffusion of Lovastatin. Samples were taken up to 48 hours for cellulose membrane and 150 hours for cadaver skin. Samples were analyzed using UV spectrophotometer at 240nm.;The obtained data showed that the drug diffusion was better from Methocell gel (0.25%) compared to other concentrations (0.125%, 0.5%, and 0.75%) of the gel. Amount released without enhancers from Lovastatin solution through cellulose membrane were found to be 2.41% and from Methocel gel through cellulose membrane is 1.15%. The drug release through human cadaver skin using (0.25%) gel is 0.49%. Caprylic acid, Capric acid, Lauric acid did not give significant increase in release through cellulose membrane as enhancer. Adding Sodium lauryl sulfate as an enhancer increased the release of drug. Release from gel through cellulose membrane was found to be 1.62% and through cadaver skin was found to be 0.72% respectively.;Doubling the enhancer concentration increased the release through cellulose membrane (1.99%) and human cadaver skin (0.96%) respectively. This study demonstrates that Lovastatin is a good candidate for making gel in transdermal drug delivery system and the amount of Lovastatin released is increasing by using the Sodium lauryl sulfate.
机译:冠心病发展的主要危险因素是高浓度的血浆胆固醇,尤其是低密度脂蛋白(LDL)胆固醇。引起心脏和血管疾病的最大原因是动脉硬化。动脉粥样硬化是无声的,冠状动脉脂肪浸润最终导致冠心病(CHD)。洛伐他汀是用于治疗该疾病的理想药物之一。本研究确定了洛伐他汀通过纤维素膜和人体尸体皮肤的透皮递送,并评估了增强剂的作用。由Franz扩散池在37°C下进行。用Methocel凝胶以四种不同浓度(0.125%,0.25%,0.5%和0.75%)配制不同浓度的洛伐他汀溶液(0.025%,0.05%和0.1%)。使用了四种浓度为0.1%的增强剂(辛酸,癸酸,月桂酸,月桂基硫酸钠)。供体隔室包含洛伐他汀溶液或凝胶。接收器隔室包含1:1比例的乙醇和水。纤维素膜和人体尸体皮肤用于研究洛伐他汀的扩散。纤维素膜的采样时间长达48小时,尸体皮肤的采样时间高达150小时。使用紫外分光光度计在240nm处分析样品;获得的数据表明,与其他浓度(0.125%,0.5%和0.75%)的凝胶相比,Methocell凝胶(0.25%)的药物扩散效果更好。在不使用增强剂的情况下,洛伐他汀溶液通过纤维素膜的释放量为2.41%,从Methocel凝胶通过纤维素膜的释放量为1.15%。使用(0.25%)凝胶通过人尸体皮肤释放的药物为0.49%。辛酸,癸酸,月桂酸没有明显增加通过纤维素膜作为增强剂的释放。加入十二烷基硫酸钠作为增强剂可增加药物的释放。从凝胶中通过纤维素膜的释放分别为1.62%和通过尸体皮肤的释放为0.72%;增强剂浓度加倍增加分别通过纤维素膜(1.99%)和人尸体皮肤(0.96%)的释放。这项研究表明,洛伐他汀是在透皮给药系统中制备凝胶的良好候选者,而洛伐他汀的释放量通过使用月桂基硫酸钠而增加。

著录项

  • 作者

    Khalafi, Samira.;

  • 作者单位

    Long Island University, The Brooklyn Center.;

  • 授予单位 Long Island University, The Brooklyn Center.;
  • 学科 Chemistry Biochemistry.;Chemistry Pharmaceutical.
  • 学位 M.S.
  • 年度 2009
  • 页码 87 p.
  • 总页数 87
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学;药物化学;
  • 关键词

  • 入库时间 2022-08-17 11:38:22

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号